Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05932199 |
|
Recruitment Status :
Not yet recruiting
First Posted : July 6, 2023
Last Update Posted : January 16, 2024
|
Sponsor:
Baylor College of Medicine
Collaborator:
Duke Cancer Institute
Information provided by (Responsible Party):
Robert Taylor Ripley, Baylor College of Medicine
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | May 31, 2028 |
| Estimated Study Completion Date : | May 31, 2028 |